Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED).

ABSTRACT:

Background

Chemohormonal therapy with androgen deprivation therapy and docetaxel (ADT + D) improves overall survival (OS) and quality of life (QOL) at 12 mo versus androgen deprivation therapy (ADT) alone in men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the prognostic role of QOL is unknown in this population.

Objective

To study the relationship between QOL, disease characteristics, and OS in men with mHSPC.

Design, setting, and participants

In this exploratory post hoc analysis, 790 patients with mHSPC completed the QOL instruments Functional Assessment of Cancer Therapy-Prostate (FACT-P), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Brief Pain Inventory (BPI).

Outcome measurements and statistical analysis

L

SUBMITTER: Sentana-Lledo D 

PROVIDER: S-EPMC11518880 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature